BioArctic AB (publ) Asset Resilience Ratio

Latest as of June 2026: 32.23%

BioArctic AB (publ) asset resilience ratio. BioArctic AB (publ) (BIOA-B) has an Asset Resilience Ratio of 32.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BioArctic AB (publ) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr908.65 Million
≈ $97.79 Million USD Cash + Short-term Investments

Total Assets

Skr2.82 Billion
≈ $303.37 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of BioArctic AB (publ) (2017–2025)

Asset resilience ratio of BioArctic AB (publ) from 2017 to 2025. This chart shows how BioArctic AB (publ)'s Asset Resilience Ratio has changed over time. See BioArctic AB (publ) (BIOA-B) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down BioArctic AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BioArctic AB (publ) (BIOA-B) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr0.00 0%
Short-term Investments Skr908.65 Million 32.23%
Total Liquid Assets Skr908.65 Million 32.23%

Asset Resilience Insights

  • Very High Liquidity: BioArctic AB (publ) maintains exceptional liquid asset reserves at 32.23% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

BioArctic AB (publ) Industry Peers by Asset Resilience Ratio

Compare BioArctic AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.57%
Eupraxia Pharmaceuticals Inc
TO:EPRX
Biotechnology 25.13%
Cabio Biotech Wuhan Co Ltd
SHG:688089
Biotechnology 3.60%

BioArctic AB (publ) Asset Resilience Ratio by Year (2017–2025)

BioArctic AB (publ) asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for BioArctic AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 85.06% Skr2.19 Billion
≈ $235.73 Million
Skr2.58 Billion
≈ $277.14 Million
+14.99pp
2024-12-31 70.07% Skr778.92 Million
≈ $83.82 Million
Skr1.11 Billion
≈ $119.63 Million
+27.91pp
2023-12-31 42.16% Skr500.00 Million
≈ $53.81 Million
Skr1.19 Billion
≈ $127.64 Million
-52.35pp
2021-12-31 94.51% Skr848.40 Million
≈ $91.30 Million
Skr897.73 Million
≈ $96.61 Million
-0.70pp
2020-12-31 95.20% Skr999.94 Million
≈ $107.61 Million
Skr1.05 Billion
≈ $113.03 Million
+1.17pp
2019-12-31 94.04% Skr1.11 Billion
≈ $119.75 Million
Skr1.18 Billion
≈ $127.35 Million
+28.19pp
2018-12-31 65.85% Skr917.31 Million
≈ $98.72 Million
Skr1.39 Billion
≈ $149.91 Million
-31.51pp
2017-12-31 97.36% Skr1.11 Billion
≈ $119.49 Million
Skr1.14 Billion
≈ $122.73 Million
--
pp = percentage points

About BioArctic AB (publ)

ST:BIOA-B Sweden Biotechnology
Market Cap
$2.56 Billion
Skr23.75 Billion SEK
Market Cap Rank
#5229 Global
#71 in Sweden
Share Price
Skr319.40
Change (1 day)
-0.25%
52-Week Range
Skr263.60 - Skr364.40
All Time High
Skr377.80
About

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for in… Read more